Article

Gavreto, FDA Approved for Treatment of Metastatic RET Fusion-Positive NSCLC, Available at Biologics by McKesson

Gavreto was granted accelerated approval by the FDA on September 4, 2020, for the treatment of adult patients with metastatic RET fusion-positive non–small cell lung cancer (NSCLC).

CARY, N.C.Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Blueprint Medicines as a specialty pharmacy provider for Gavreto (pralsetinib) for the treatment of adult patients with metastatic RET fusion-positive non–small cell lung cancer (NSCLC) as detected by an FDA-approved test.

Gavreto, which was granted accelerated approval by the FDA on September 4, 2020, was specifically designed to inhibit RET alterations. RET fusions are oncogenic drivers for multiple solid tumor types. This drug was given priority review by the FDA, which is granted to drugs that are expected to have a large impact on a disease’s treatment.

“Gavreto gives patients a new RET inhibitor option for treating their RET-driven metastatic NSCLC,” said Allison Kinnarney, director of Clinical Programs with Biologics.


Learn more.

Related Videos
Andrew Kuykendall, MD, Moffitt Cancer Center
Joshua Kaufman, MD, CDPHP
Cathy Eng, MD, FACP, FASCO
Andrew Kuykendall, MD, Moffitt Cancer Center
Frederick L. Locke, MD, Moffitt Cancer Center and Research Institute
Jorge García, PharmD, MS, MBA, MHA, FACHE, FACCC
Douglas Flora, MD, FACCC
rachel rohaidy
Douglas Flora, MD, FACCC
Fred Locke, MD, Moffitt Cancer Center and Research Institute
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo